… ) and Middle East respiratory syndrome, as well as the current pandemic of SARS
coronavirus 2 (SARS-CoV-2) 1,2,3,4 . Vaccines that elicit protective immunity against …

… high titers of neutralizing SARS-CoV-2 antibodies, no overall … tract, influence SARS-CoV-2
antibody development or serum … had potent neutralizing SARS-CoV-2 antibodies at hospital …

… Further, the S protein of SARS-CoV-2 is the main target for neutralizing antibodies, and
several recombinant neutralizing antibodies have been granted Emergency Use Authorization (…

… -CoV cross-reactive antibodies as well as a large pool of SARS-CoV-2 broadly neutralizing
antibodies … These bNAbs are ultrapotent against circulating SARS-CoV-2 variants of concern (…

… located in antigenic sites recognized by antibodies with potent neutralizing activity. We used
serum … to assess neutralizing activity against the SARS-CoV-2 variants in a live-virus assay. …

… the neutralizing abilities of most of the other antibodies. We also find that 515-5 could cross
neutralize the SARS-CoV … neutralizing antibodies for COVID-19 as therapeutic candidates. …

… titres fell 4.9-fold to a median titre of 21.3 (neutralization dose 80%), with 21.6% … neutralizing
antibodies at the later time point. Next, we examined neutralization of 21 distinct SARS-CoV-…

… of Omicron to evade immunity from neutralizing antibodies, produced by natural infection
and/or … capacity of SARS-CoV-2, with an emphasis on the neutralizing antibodies generated by …

… functional neutralizing antibodies. The most remarkable finding of this study was the significantly
lower neutralizing antibody titer against B.1.351 lineage, compared to the wild-type virus…

… The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China … antibody
that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody …